NCT00410605View on ClinicalTrials.gov

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2011

Study Completion Date

June 30, 2014

Conditions
Multiple Myeloma in RelapseStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
BIOLOGICAL

bevacizumab

Given IV

DRUG

lenalidomide

Given orally

DRUG

dexamethasone

Given orally

Trial Locations (2)

15232

University of Pittsburgh Cancer Institute, Pittsburgh

53792

University of Wisconsin Hospital and Clinics, Madison

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00410605 - Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma | Biotech Hunter | Biotech Hunter